Luciano S.
- Country
- Italy
- Department
- Medical Oncology
Research Overview
- Phase III Randomized Trial of Docetaxel plus Apalutamide Intensification in Metastatic Hormone-Sensitive Prostate Cancer with Inadequate PSA Response
- Randomized, Open-Label, Multicenter Study of Docetaxel Versus Abiraterone or Enzalutamide in Metastatic Castration-Resistant Prostate Cancer with Adverse Prognostic Factors
Data & Insights
Has run more than one trial at 4 of 82 partner sites.
Specializations
Oncological Focus
This investigator specializes in treating metastatic castration resistant prostate cancer, with particular emphasis on cases without BRCA1/2 gene mutations.
- Advanced Prostate Cancer Management
- Hormone-Resistant Disease
- Genetic Profiling in Cancer
The investigator evaluates therapeutic approaches for advanced prostate cancer patients focusing on optimal treatment sequencing.
Therapeutic Expertise
Demonstrates significant experience in managing hormone-resistant cancers through various therapeutic modalities, including both chemotherapy and targeted treatments.
- Chemotherapy Protocols
- Hormone Therapy
- Targeted Therapies
The investigator explores comparative effectiveness of different treatment strategies in advanced prostate cancer.
Treatment Innovation
Focuses on developing personalized treatment approaches for patients with specific prognostic factors in prostate cancer.
- Treatment Sequencing
- Prognostic Assessment
- Clinical Outcomes
The investigator evaluates novel therapeutic strategies for optimizing patient outcomes in advanced disease states.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.